T1	Participants 68 101	patients with Parkinson's disease
T2	Participants 256 289	patients with Parkinson's disease
T3	Participants 323 367	10 patients with a moderate motor impairment
T4	Participants 462 517	eight patients with L-dopa-induced peak-dose dyskinesia
T5	Participants 754 793	motor impairment in Parkinson's disease
